Next Article in Journal
Vaccine Composition Formulated with a Novel Lactobacillus-Derived Exopolysaccharides Adjuvant Provided High Protection against Staphylococcus aureus
Next Article in Special Issue
Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities
Previous Article in Journal
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 9
Issue 7
10.3390/vaccines9070774
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity

by
Seth H. Pincus
1,*,
Ryan B. Craig
2,3,
Lauren Weachter
2,
Celia C. LaBranche
4,
Rafiq Nabi
5,
Connie Watt
1,
Mark Raymond
1,
Tami Peters
1,
Kejing Song
2,
Grace A. Maresh
2,
David C. Montefiori
4 and
Pamela A. Kozlowski
5
1
Department of Chemistry and Biochemistry, Montana State University, Bozeman, MT 59715, USA
2
Research Institute for Children, Children’s Hospital, New Orleans, LA 70118, USA
3
Department of Pathology, Tulane University, New Orleans, LA 70112, USA
4
Department of Surgery, Duke University, Durham, NC 27707, USA
5
Department of Microbiology, Immunology, and Parasitology, LSU School of Medicine, New Orleans, LA 70112, USA
*
Author to whom correspondence should be addressed.
Vaccines 2021, 9(7), 774; https://doi.org/10.3390/vaccines9070774
Submission received: 1 June 2021 / Revised: 2 July 2021 / Accepted: 5 July 2021 / Published: 12 July 2021
(This article belongs to the Special Issue Advances in Antibody Based HIV-1 Vaccine Development)
Browse Figures
Versions Notes

Abstract

We have constructed bispecific immunoglobulin-like immunoadhesins that bind to both the HIV-envelope glycoproteins: gp120 and gp41. These immunoadhesins have N terminal domains of human CD4 engrafted onto the N-terminus of the heavy chain of human anti-gp41 mAb 7B2. Binding of these constructs to recombinant Env and their antiviral activities were compared to that of the parental mAbs and CD4, as well as to control mAbs. The CD4/7B2 constructs bind to both gp41 and gp140, as well as to native Env expressed on the surface of infected cells. These constructs deliver cytotoxic immunoconjugates to HIV-infected cells, but not as well as a mixture of 7B2 and sCD4, and opsonize for antibody-mediated phagocytosis. Most surprisingly, given that 7B2 neutralizes weakly, if at all, is that the chimeric CD4/7B2 immunoadhesins exhibit broad and potent neutralization of HIV, comparable to that of well-known neutralizing mAbs. These data add to the growing evidence that enhanced neutralizing activity can be obtained with bifunctional mAbs/immunoadhesins. The enhanced neutralization activity of the CD4/7B2 chimeras may result from cross-linking of the two Env subunits with subsequent inhibition of the pre-fusion conformational events that are necessary for entry.
Keywords: HIV; immunotherapy; immunoadhesin; AIDS HIV; immunotherapy; immunoadhesin; AIDS

Share and Cite

MDPI and ACS Style

Pincus, S.H.; Craig, R.B.; Weachter, L.; LaBranche, C.C.; Nabi, R.; Watt, C.; Raymond, M.; Peters, T.; Song, K.; Maresh, G.A.; et al. Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity. Vaccines 2021, 9, 774. https://doi.org/10.3390/vaccines9070774

AMA Style

Pincus SH, Craig RB, Weachter L, LaBranche CC, Nabi R, Watt C, Raymond M, Peters T, Song K, Maresh GA, et al. Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity. Vaccines. 2021; 9(7):774. https://doi.org/10.3390/vaccines9070774

Chicago/Turabian Style

Pincus, Seth H., Ryan B. Craig, Lauren Weachter, Celia C. LaBranche, Rafiq Nabi, Connie Watt, Mark Raymond, Tami Peters, Kejing Song, Grace A. Maresh, and et al. 2021. "Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity" Vaccines 9, no. 7: 774. https://doi.org/10.3390/vaccines9070774

APA Style

Pincus, S. H., Craig, R. B., Weachter, L., LaBranche, C. C., Nabi, R., Watt, C., Raymond, M., Peters, T., Song, K., Maresh, G. A., Montefiori, D. C., & Kozlowski, P. A. (2021). Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity. Vaccines, 9(7), 774. https://doi.org/10.3390/vaccines9070774

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop